Aurobindo Pharma Share Price

Agile Pharma BV, a wholly-owned step-down arm of Aurobindo, has incorporated a new subsidiary in France, Arrow Pharma Production SAS, for this

• Business Line
• 1 week ago

Pharmaceuticals company Aurobindo Pharma announced Q4FY26 & FY26 results Standalone Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 27,865.5 million, compared to Rs 27,472.8 million in Q3FY26 (QoQ increase of 1.43%) and Rs 27,319.9 million in Q4FY25 (YoY increase of 2.00%). FY26: Rs 1,11,717.2 million, compared to Rs 1,09,333.0 million in FY25 (YoY increase of 2.18%). Total Income: Q4FY26: Rs 30,006.4 million, compared to Rs 28,774.3 million in Q3FY26 (QoQ increase of 4.28%) and Rs 28,459.7 million in Q4FY25 (YoY increase of 5.43%). FY26: Rs 1,17,592.5 million, compared to Rs 1,12,614.2 million in FY25 (YoY increase of 4.42%). Profit After Tax (PAT): Q4FY26: Rs 6,922.3 million, compared to Rs 5,820.7 million in Q3FY26 (QoQ increase of 18.93%) and Rs 4,081.7 million in Q4FY25 (YoY increase of 69.60%). FY26: Rs 24,148.0 million, compared to Rs 17,467.9 million in FY25 (YoY increase of 38.24%). Consolidated Financial Highlights: Total Revenue from Operations: Q4FY26: Rs 88,533.4 million, compared to Rs 86,459.0 million in Q3FY26 (QoQ increase of 2.40%) and Rs 83,821.2 million in Q4FY25 (YoY increase of 5.62%). FY26: Rs 3,36,530.8 million, compared to Rs 3,17,237.3 million in FY25 (YoY increase of 6.08%). Total Income: Q4FY26: Rs 89,703.8 million, compared to Rs 88,335.4 million in Q3FY26 (QoQ increase of 1.55%) and Rs 85,169.3 million in Q4FY25 (YoY increase of 5.32%). FY26: Rs 3,41,451.7 million, compared to Rs 3,23,455.8 million in FY25 (YoY increase of 5.56%). Profit After Tax (PAT): Q4FY26: Rs 9,208.4 million, compared to Rs 9,098.0 million in Q3FY26 (QoQ increase of 1.21%) and Rs 9,028.3 million in Q4FY25 (YoY increase of 1.99%). FY26: Rs 35,029.7 million, compared to Rs 34,835.7 million in FY25 (YoY increase of 0.56%). Business Highlights: Segment Reporting: The company operates in only one reportable segment, 'Pharmaceuticals', in accordance with Ind AS 108, "Operating Segment". Corporate Developments: The Board of Directors approved a buyback of 5,423,728 fully paid-up equity shares of face value of Rs 1 each for an aggregate value not exceeding Rs 8,000.0 million on April 06, 2026. This was paid to eligible shareholders on May 07, 2026. The domestic branded generic pharmaceutical formulations business was transferred to Auropharm Limited (a wholly-owned subsidiary) on a going concern basis via a slump sale effective April 01, 2026. Effective January 01, 2026, Auropharm Limited acquired the non-oncology prescription formulations business from M/s Khandelwal Laboratories Private Limited for a total consideration of Rs 3,250 million. Labour Codes Impact: The company recognized an incremental gratuity and leave liability aggregating to Rs 173.8 million in the Standalone financial results and Rs 653.3 million in the Consolidated financial results for the quarter ended December 31, 2025 and year ended March 31, 2026, due to the notification of Labour Codes. This has been presented as "Exceptional Items" K. Nithyananda Reddy, Vice-Chairman & Managing Director, said: “We are encouraged by our performance for the quarter and the year, reflecting the resilience of our business model and the strength of our extensive product portfolio. Consistent volumes coupled with improved operating efficiencies, and disciplined execution have contributed positively to our results. With ongoing investments in capacity expansion and the stabilization of recently commercialized facilities, we remain confident in our ability to support sustainable growth and create long-term value for our stakeholders.” Result PDF

• Trendlyne
• 1 week ago

It will construct a greenfield mammalian drug substance manufacturing facility with $150-$175 million

• Business Line
• 1 month 2 weeks ago